Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation

Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation

In this study, we aim to explore the beneficial therapeutic impacts of dapagliflozin (Dapa), a highly potent, reversible, and selective sodium–glucose cotransporter-2 inhibitor, and liraglutide (Lira), a glucagon-like peptide-1 (GLP-1) receptor agonist, as hypoglycaemic agents for the management of...

Full description

Bibliographic Details
Main Authors: Mohamed El-Sherbiny, Mohamed El-Shafey, Eman Said, Gehan Ahmed Shaker, Mohamed El-Dosoky, Hasnaa Ali Ebrahim, Sally Yussef Abed, Khalid M. Ibraheem, Ahmed Mohsen Faheem, Muntazar AlMutawa, Bayader Alatawi, Nehal M. Elsherbiny
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Life
Subjects:
dapagliflozin
liraglutide
NF-κB
hepato-renal
cleaved caspase-3
Online Access:https://www.mdpi.com/2075-1729/12/5/764

Internet

https://www.mdpi.com/2075-1729/12/5/764

Similar Items